These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24988578)

  • 1. New FDA breakthrough-drug category--implications for patients.
    Murray BE
    N Engl J Med; 2014 Jul; 371(1):88. PubMed ID: 24988578
    [No Abstract]   [Full Text] [Related]  

  • 2. New FDA breakthrough-drug category--implications for patients.
    Ricart AD
    N Engl J Med; 2014 Jul; 371(1):89. PubMed ID: 24988580
    [No Abstract]   [Full Text] [Related]  

  • 3. New FDA breakthrough-drug category--implications for patients.
    Velleca M
    N Engl J Med; 2014 Jul; 371(1):88-9. PubMed ID: 24988579
    [No Abstract]   [Full Text] [Related]  

  • 4. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Jul; 371(1):89-90. PubMed ID: 24988576
    [No Abstract]   [Full Text] [Related]  

  • 5. New FDA breakthrough-drug category--implications for patients.
    McClellan M; Sigal E
    N Engl J Med; 2014 Jul; 371(1):87-8. PubMed ID: 24988577
    [No Abstract]   [Full Text] [Related]  

  • 6. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
    [No Abstract]   [Full Text] [Related]  

  • 7. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 8. The "in-between" new drug application.
    Novack GD
    Ocul Surf; 2009 Jan; 7(1):53-4. PubMed ID: 19214352
    [No Abstract]   [Full Text] [Related]  

  • 9. The History and Political Economy of the Hatch-Waxman Amendments.
    Lietzan E
    Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
    [No Abstract]   [Full Text] [Related]  

  • 10. Notification vs approval.
    Novack GD
    Ocul Surf; 2007 Jul; 5(3):255-8. PubMed ID: 17660899
    [No Abstract]   [Full Text] [Related]  

  • 11. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 12. Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Nov; 81(226):84465-77. PubMed ID: 27906534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA treads delicate line between safety and speed.
    Oncology (Williston Park); 1999 Jan; 13(1):16. PubMed ID: 10027195
    [No Abstract]   [Full Text] [Related]  

  • 16. The IND application.
    Ferkany JW; Williams M
    Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 18. Legislative reform proposals.
    Bruderle TP
    Am J Health Syst Pharm; 1996 Sep; 53(17):2083-7. PubMed ID: 8870897
    [No Abstract]   [Full Text] [Related]  

  • 19. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 20. Disqualification of a clinical investigator--FDA. Final rule.
    Fed Regist; 1997 Sep; 62(172):46875-6. PubMed ID: 10173286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.